Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History RARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics RARE

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Ultragenyx

RARE
Current price
27.41 USD +0.05 USD (+0.18%)
Last closed 27.31 USD
ISIN US90400D1081
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 581 942 016 USD
Yield for 12 month -35.93 %
1Y
3Y
5Y
10Y
15Y
RARE
21.11.2021 - 28.11.2021

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California. Address: 60 Leveroni Court, Novato, CA, United States, 94949

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

89.84 USD

P/E Ratio

Dividend Yield

Financials RARE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures RARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+560 230 000 USD

Last Year

+434 249 000 USD

Current Quarter

+139 292 000 USD

Last Quarter

+164 877 000 USD

Current Year

+483 502 000 USD

Last Year

+389 040 000 USD

Current Quarter

+110 630 000 USD

Last Quarter

+147 983 000 USD
EBITDA -477 876 992 USD
Operating Margin TTM -102.62 %
Price to Earnings
Return On Assets TTM -24.51 %
PEG Ratio -0.24
Return On Equity TTM -377.06 %
Wall Street Target Price 89.84 USD
Revenue TTM 590 689 024 USD
Book Value 1.54 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 28.00 %
Dividend Yield
Gross Profit TTM -182 318 000 USD
Earnings per share -5.83 USD
Diluted Eps TTM -5.83 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -93.04 %

Stock Valuation RARE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.60
Price Sales TTM 4.37
Enterprise Value EBITDA -6.46
Price Book MRQ 17.90

Technical Indicators RARE

For 52 Weeks

26.85 USD 60.37 USD
50 Day MA 36.39 USD
Shares Short Prior Month 6 081 072
200 Day MA 42.56 USD
Short Ratio 5.87
Shares Short 6 820 252
Short Percent 6.66 %